November 7th 2024 Program NIRO Annual Meeting
Program
|
08:00-09:00 |
Registration and coffee |
|
09:00-09:10 |
Welcome: NIRO network leader Heidi Lyng |
|
09:10-10:10 |
Geoff Higgins: Atovaquone as a hypoxia modifier: from compound screen to clinical trials. |
|
10:10-10:35 |
Vilde Drageset Haakensen: Combination of immunotherapy and radiotherapy for the treatment of lung cancer - where do we go from here? |
|
10:35-11:00 |
Coffee break |
|
11:00-11:20 |
Oral presentations (7 + 3 min)
Chloé Müller: Combined treatment with radiation and ATM inhibition induces interferon immune signaling from NSCLC-derived cancer-associated fibroblasts. Tord Hompland: MRI of pretreatment hypoxia and early response assessment in cervical cancer. |
|
11:20-11:45 |
Cecilia Futsæther: The lure of artificial intelligence: Opportunities and challenges in radiotherapy. |
|
11:45-12:45 |
Lunch |
|
12:45-13:45 |
Karin Haustermans: Protontherapy in Europe: How can we move forward? |
|
13:45-14:10 |
Judith Reindl: The Best of Two Worlds – Combining FLASH and Spatial Fractionation in Proton Therapy. |
|
14:10-14:25 |
Silje Skjelsvik Os: Survival prediction in patients with gynecological cancer irradiated for brain metastases. |
|
14:25-14:40 |
Flash poster presentations |
|
14:40-15:20 |
Poster presentations on stand and coffee |
|
15:20-15:45 |
Karsten Rydén-Eilertsen: Proton therapy: why, how, and for whom? |
|
15:45-16:15 |
Oral presentations (7 + 3 min) Anne Marit Rykkelid: The Relative Biological Effectiveness of low energy protons is dependent on the linear energy transfer (LET). Taran Paulsen Hellebust: Initial analysis of PRO-GLIO patients: dose distribution and LET-weighted dose. Anna Julie Kjøl Høyvik: Superior therapeutic efficacy of PSMA-targeting alpha-emitting radioligand 212Pb-AB001 compared to beta-emitting 177Lu-PSMA-617 in a micrometastatic model of prostate cancer.
|
|
16:15-16:25 |
René van Helvoirt: Enhancing Radiotherapy Education: The Nordic Radiotherapy Diploma Program (NORTHDIP) Initiative. |
|
16:25-16:35 |
TBD: National expert group for radiation therapy research (NERR) |
|
16:35-16:45 |
Closing remarks / Heidi Lyng |